Read More 1 minute read Analyst Ratings News Price Target Reiteration Morgan Stanley Reiterates Equal-Weight on Hertz Global Holdings, Maintains $20 Price Target By Benzinga Newsdesk February 7, 9:46 AM Morgan Stanley analyst Adam Jonas reiterates Hertz Global Holdings (NASDAQ:HTZ) with a Equal-Weight and maintains $20 price target. HTZ
Read More 1 minute read Analyst Ratings News Price Target Reiteration Mizuho Reiterates Buy on Atara Biotherapeutics, Maintains $31 Price Target By Benzinga Newsdesk February 7, 9:19 AM Mizuho analyst Salim Syed reiterates Atara Biotherapeutics (NASDAQ:ATRA) with a Buy and maintains $31 price target. ATRA
Read More 1 minute read Analyst Ratings News Price Target Reiteration Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeutics, Maintains $38 Price Target By Benzinga Newsdesk February 7, 8:42 AM Cantor Fitzgerald analyst Louise Chen reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight and maintains $38 price target. ACRS
Read More 1 minute read Analyst Ratings News Price Target Reiteration Cantor Fitzgerald Reiterates Overweight on Neurocrine Biosciences, Lowers Price Target to $127 By Benzinga Newsdesk February 7, 8:35 AM Cantor Fitzgerald analyst Charles Duncan reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $132 to $127. NBIX
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Pulmatrix, Maintains $10 Price Target By Benzinga Newsdesk February 7, 7:40 AM HC Wainwright & Co. analyst Andrew Fein reiterates Pulmatrix (NASDAQ:PULM) with a Buy and maintains $10 price target. PULM
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $35 Price Target By Benzinga Newsdesk February 7, 7:28 AM HC Wainwright & Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $35 price target. VRDN
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on 89bio, Maintains $27 Price Target By Benzinga Newsdesk February 7, 7:26 AM HC Wainwright & Co. analyst Ed Arce reiterates 89bio (NASDAQ:ETNB) with a Buy and maintains $27 price target. ETNB
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $140 Price Target By Benzinga Newsdesk February 7, 7:22 AM HC Wainwright & Co. analyst Andrew Fein reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and maintains $140 price target. NBIX
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Context Therapeutics, Maintains $4 Price Target By Benzinga Newsdesk February 7, 7:20 AM HC Wainwright & Co. analyst Emily Bodnar reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $4 price target. CNTX
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target By Benzinga Newsdesk February 7, 7:18 AM HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:LIFE) with a Buy and maintains $35 price target. LIFE